AUROPHARMA.NSAUROPHARMA.NSNSE
Loading
Year-over-year research & development expense growth
Latest
-1.21%
↓ 110% vs avg
Percentile
P36
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
12.34%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -1.21% |
| Q3 2025 | 12.81% |
| Q2 2025 | -78.31% |
| Q1 2025 | 0.00% |
| Q4 2024 | 0.00% |
| Q3 2024 | 0.00% |
| Q2 2024 | -100.00% |
| Q1 2024 | 0.00% |
| Q4 2023 | 0.00% |
| Q3 2023 | 0.00% |
| Q2 2023 | -100.00% |
| Q1 2023 | 249.91% |
| Q4 2022 | 0.00% |
| Q3 2022 | -100.00% |
| Q2 2022 | -80.92% |
| Q1 2022 | 313.39% |
| Q4 2021 | -1.50% |
| Q3 2021 | 11.45% |
| Q2 2021 | -76.51% |
| Q1 2021 | 290.28% |
| Q4 2020 | -4.17% |
| Q3 2020 | 60.12% |
| Q2 2020 | -73.53% |
| Q1 2020 | 279.74% |
| Q4 2019 | 13.59% |
| Q3 2019 | -8.27% |
| Q2 2019 | -72.02% |
| Q1 2019 | 241.12% |
| Q4 2018 | 17.44% |
| Q3 2018 | 0.00% |
| Q2 2018 | -100.00% |
| Q1 2018 | 0.00% |
| Q4 2017 | 0.00% |
| Q3 2017 | 0.00% |
| Q2 2017 | -100.00% |
| Q1 2017 | 0.00% |
| Q4 2016 | 0.00% |
| Q3 2016 | 0.00% |
| Q2 2016 | -100.00% |
| Q1 2016 | 0.00% |